What Cardio Intelligence does
Cardio Intelligence develops SmartRobin, an AI-powered long-term electrocardiogram (ECG) analysis system aimed at closing gaps in cardiac-disease diagnosis. The company says it applies explainable AI to support physicians reading long-term ECG recordings, and a pre-disease diagnosis support AI to detect indicators of paroxysmal atrial fibrillation in patients without symptoms. As of November 2025 the SmartRobin AI series had been introduced at more than 150 medical institutions in Japan, according to the company. Cardio Intelligence is co-developing AI-based long-term ECG analysis technology with Shin Nippon Biomedical Laboratories, its Series B lead investor.
Cardio Intelligence is a healthcare tool on Falcoscan. AI that analyzes long-term ECG recordings to catch heart disease earlier. Falcoscan rates Cardio Intelligence with an Opportunity score of 84/100, a Saturation score of 11/100, and a Wrapper-risk score of 9/100. Market signal: rising. Cardio Intelligence is founded in 2019, currently at Series_b stage. Pricing: Paid.